Chronic myelomonocytic leukemia in the light of the WHO proposals.
The WHO classification moved CMML to myeloproliferative/myelodysplastic disorders, and defined CMML I and CMML II according to medullary and peripheral blast count. To confirm these proposals, we analyzed 266 patients with CMML I and 73 patients with CMML II. Median survival time was 20 months for CMML I, and 15 months for CMML II (p<0.005). The cumulative risk of AML evolution differed between patient groups (p=0,001). No conclusive differences in clinical, morphologic, hematologic or cytogenetic parameters were found. These data support the WHO proposals for the classifi-cation of CMML.
Germing
Ulrich
U
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany. germing@med.uni-duesseldorf.de
Strupp
Corinna
C
Knipp
Sabine
S
Kuendgen
Andrea
A
Giagounidis
Aristoteles
A
Hildebrandt
Barbara
B
Aul
Carlo
C
Haas
Rainer
R
Gattermann
Norbert
N
Bennett
John M
JM
D002965:Classification; D006801:Humans; D015477:Leukemia, Myelomonocytic, Chronic / Q000145:classification*; D009196:Myeloproliferative Disorders / Q000145:classification; D014944:World Health Organization